Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Drug Discovery
- Central Nervous System
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 377097
VRP324 is a drug product candidate based on nanotechnology which enables the delivery of CBD into the brain via intranasal delivery for the management of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older, as well as patients one year of age and older who experience seizures associated with Lennox-Gastaut syndrome ( LGS) or Dravet syndrome. VRP324 is manufactured using high pressure homogenization and spray drying. In animal studies, the MET nanoparticles are well-tolerated via the nasal route at the dose administered.
Field of use is for the treatment of seizures associated with tuberous sclerosis complex (TSC) Lennox-Gastaut syndrome and Dravet syndrome in patients one year of age and older.
Lennox-Gastaut syndrome and Dravet syndrome are rare central nervous system diseases considered serious epileptic encephalopathies that cause different types of epileptic seizures as well as cognitive and behavioral changes and are generally resistant to treatment.
Tuberous sclerosis complex (TSC) is a hereditary condition associated with changes in the skin, brain, kidney, and heart. Seizures are a frequent complication, and some people with TSC have learning disabilities. Skin changes are the most noticeable sign of TSC and appear in nearly all people with the condition.
IPSCIO Record ID: 305651
Licensor is a pharmaceutical company with a focus in CNS (central nervous system), Dermatology, and Pediatrics.
IPSCIO Record ID: 204556
Biphasixâ„¢ is a needle-free, noninvasive, particulate drug delivery system suitable for intra- and transdermal delivery of drugs.
BiPhasixâ„¢ can entrap and transport pharmaceutical products through the skin to achieve therapeutic benefit in a wide range of indications. Studies have shown that BiPhasixâ„¢ can significantly enhance the bioavailability of many drugs, leading to improved clinical outcomes. In addition, this proprietary technology can serve as an alternative dosage form to injectables by providing less invasive routes of administration such as dermal, transdermal, nasal, vaginal, ocular, and rectal.
The Company will use for the delivery and commercialization of cannabinoid, cannabidiol and tetrahydrocannabinol-based products.
IPSCIO Record ID: 343475
IPSCIO Record ID: 319229
Intellectual Property includes but not limited to the US Patent Nos. 8,278,277. This covers lipophilic derivatives of hydrophilic drugs comprising a hydrophilic drug and a cleavable linker as well as methods of treatment using these compositions. In particular the patents relate to compositions of a lipophilic derivative of the hydrophilic neuropeptide Leucine -Enkephalin and an amphiphile compound, where the derivative includes a lipophilic linker attached to the side chain oxygen of the tyrosine in the Leucine -Enkephalin, and where the amphiphile compound is quaternary palmitoyl glycol chitosan (GCPQ).
8,278,277 – Delivery of hydrophilic drugs
Licensor is a leader in pharmaceutical nanotechnology. The nanomedicines know-how and proprietary technology platforms provide drug delivery solutions for poorly water soluble drugs, nucleic acids and peptides.
IPSCIO Record ID: 390198
Dravet syndrome is an early childhood-onset CNS disease that results in severe epileptic seizures typically occurring within the first year after birth. Incidence for Dravet syndrome is approximately 115,000 in the United States, and 90% of the associated mutations are de novo (not passed from a parent). Mortality rate for Dravet syndrome patients is higher than general epilepsy patients, with a rate of 15-20% by adulthood. The disease is genetically linked, with 70% to 85% of cases characterized by mutations in the SCN1A gene. Mutations cause defects in the function of the sodium ion channel. Seizures due to Dravet syndrome are typically difficult to control and require life-long treatment.
Purchased Rights means the right to receive one hundred percent (100%) of (i) all milestone payments paid, owed, or otherwise payable by Party C under the Transaction Agreement on or after the date of this Agreement, (ii) all royalties paid, owed or otherwise payable by Party C under Section 8.3 of the Transaction Agreement on or after the date of this Agreement, (iii) all amounts paid, owed or otherwise payable by Party C under the Transaction Agreement on or after the date of this Agreement, (iv) all amounts paid, owed or otherwise payable by Party C of the Transaction Agreement (other than amounts for audit costs) with respect to such milestone payments and/or royalties, (v) all interest paid, owed or otherwise payable by Party C of the Transaction Agreement with respect to such milestone payments and/or royalties, and (vi) all amounts equal to the royalty payable under the Transaction Agreement with respect to all proceeds (including any damages, monetary awards or other amounts recovered, whether by judgment or settlement) deemed Net Sales pursuant to Section 10.3(d) of the Transaction Agreement.
Dravet syndrome is characterized by mutations in the sodium ion channel, the ion channel critical for the generation and propagation of action potentials in neurons, and which ordinarily plays a crucial role inhibitory signaling.